Serotonin is an important gastrointestinal signaling molecule. It is a paracrine messenger
utilized by enterochromaffin (EC) cells, which function as sensory transducers. Serotonin …

Hydroxytryptamine4 (5‐HT4) receptors are an interesting target for the management of
patients in need of gastrointestinal (GI) promotility treatment. They have proven therapeutic …

Background Acute colonic pseudo-obstruction is characterized by clinical and radiological
evidence of acute large bowel obstruction in the absence of a mechanical cause. The …

Irritable bowel syndrome (IBS) is common and can be disabling. Several drugs that
modulate serotonin (5HT) and other neurotransmitters in the gut (neuroenteric modulators) …

Background The main symptom of postoperative ileus (POI) is an intestinal motility disorder
in which monocytes/macrophages and neutrophils play crucial roles. Prokinetic 5 …

Although the past few years have seen an exponential growth of compounds of potential
interest for the treatment of functional gastrointestinal (GI) tract disorders, the gap that still …

Prucalopride is a novel enterokinetic compound and is the first representative of the
benzofuran class. We set out to establish its pharmacological profile in various receptor …

Acute colonic pseudo‐obstruction (Ogilvie's syndrome) can be defined as a clinical
condition with symptoms, signs and radiological appearance of acute large bowel …

5‐Hydroxytryptamine (5‐HT) is known to produce a number of different effects in the
gastrointestinal tract of various species, and has been proposed to play a key role in a …

Recent research has provided new information about drugs that could be used to treat
functional motility disorders. Promotility drugs accelerate gastric emptying or colonic transit …